Cardio Diagnostics, Inc, a biotechnology company making cardiovascular disease prevention and early detection more accessible, personalized and precise, announces the launch of its patent-pending ...
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, and Family Medicine Specialists (FMS), a ...
Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, is making progress in gaining broad access to Medicare reimbursement for its Epi+Gen CHD™ and ...
The final gapfill payment rate for both the Epi+Gen CHD™ and PrecisionCHD™ tests is higher at $854 compared to the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for ...
Deepak L. Bhatt, MD, MPH: Let me turn now to Dr Navar to discuss what I think is an important part of the discussion. She’s done a lot of work on this. How do we actually estimate patients’ risk for ...
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in most developed countries. Among markers of CVD, arterial stiffness has proven to be an important parameter in the ...
Obtaining the payment rates marks a key milestone in gaining broad access to Medicare reimbursement. CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc. (CDIO) (Nasdaq: CDIO), an AI-powered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback